BRAF and neoplasm: Several targeted therapies have been approved for the treatment of NSCLC harboring certain genetic variations in EGFR, ALK, ROS1, or BRAF [5–9] and it is required to determine the existence of those genetic variations in tumor before targeted therapies are given to patients.